Article History
Accepted: 10 September 2022
First Online: 18 October 2022
Declarations
:
: No external funding was used in the preparation of this article.
: The authors declare that they have no direct competing interests. Misako Nagasaka has received honorarium from Astra Zeneca (ad-board), Caris Life Sciences (consultant), Lilly (consultant), Daiichi Sankyo (ad-board), Takeda (speaker), Novartis (ad-board), EMD Serono (ad-board), Blueprint Medicines (speaker), Janssen (ad-board), Pfizer (ad-board), Genentech (ad-board), and Mirati (ad-board) and has received travel support from AnHeart Therapeutics. Other authors have no potential conflicts of interest to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: DB provided clinical interpretation and drafted and reviewed all versions of the manuscript. GK drafted and reviewed all versions of the manuscript. MN provided clinical interpretation and drafted and reviewed all versions of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.